English
Insider transactions
EDGAREdgewise Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 34 transactions, 485,784.00 shares
- Sum of shares × price per share: 17,630,730.3316
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 105
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 Filed 2026-11-18 | Donovan Joanne M. Officer: CMO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 854.00 | 45.48 | 38,839.92Derived: shares × price per share. Exact value 38839.9200. | 8,139.00 | Direct (D) | Yes | F1, F2
| Open filing 0001644087-26-000007 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-10 | Nofi Michael Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 10,937.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 10,937.00 | Direct (D) | No | — | Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-10 | Nofi Michael Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,442.00 | 45.427 | 201,786.734Derived: shares × price per share. Exact value 201786.73400. | 6,495.00 | Direct (D) | No | F1, F2
| Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-10 | Nofi Michael Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 10,937.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 32,813.00 | Direct (D) | No | F3
| Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row |
| 2026-10-01 Filed 2026-10-02 | Fox Jonathan C Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 308.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 25,141.00 | Direct (D) | No | — | Open filing 0001655016-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-13 Filed 2026-08-14 | Donovan Joanne M. Officer: CMO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,919.00 | 43.4065 | 126,703.5735Derived: shares × price per share. Exact value 126703.573500. | 8,625.00 | Direct (D) | No | F7, F8
| Open filing 0001644087-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-17 | MOORE JOHN R Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,000.00 | Direct (D) | No | F1
| Open filing 0001191702-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-17 | Derakhshan Behrad Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 100,000.00 | Direct (D) | No | F1
| Open filing 0001853109-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-17 | Nofi Michael Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 48,750.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 48,750.00 | Direct (D) | No | F1
| Open filing 0001705477-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-17 | Donovan Joanne M. Officer: CMO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,000.00 | Direct (D) | No | F1
| Open filing 0001644087-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-17 | Russell Alan J Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,000.00 | Direct (D) | No | F1
| Open filing 0001853529-26-000003 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 30,336.00 | Direct (D) | No | — | Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 7,031.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 37,367.00 | Direct (D) | No | — | Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,238.00 | 43.6775 | 141,427.745Derived: shares × price per share. Exact value 141427.745000. | 34,129.00 | Direct (D) | No | F1, F2
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,273.00 | 43.6759 | 99,275.3207Derived: shares × price per share. Exact value 99275.320700. | 31,856.00 | Direct (D) | No | F1, F3
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 390.00 | 44.46 | 17,339.4Derived: shares × price per share. Exact value 17339.4000. | 31,466.00 | Direct (D) | No | F1
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 11,563.00 | Direct (D) | No | F4
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 7,031.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 21,094.00 | Direct (D) | No | F5
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 32,500.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 32,500.00 | Direct (D) | No | F6
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Russell Alan J Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,000.00 | Direct (D) | No | F7
| Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 29,426.00 | Direct (D) | No | — | Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 7,500.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 36,926.00 | Direct (D) | No | — | Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,171.00 | 43.7934 | 95,075.4714Derived: shares × price per share. Exact value 95075.471400. | 34,755.00 | Direct (D) | No | F1, F2
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 304.00 | 44.5018 | 13,528.5472Derived: shares × price per share. Exact value 13528.547200. | 34,451.00 | Direct (D) | No | F1, F3
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 150.00 | 44.4433 | 6,666.495Derived: shares × price per share. Exact value 6666.495000. | 34,301.00 | Direct (D) | No | F1, F4
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,475.00 | 43.6984 | 108,153.54Derived: shares × price per share. Exact value 108153.540000. | 31,826.00 | Direct (D) | No | F1, F5
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 11,563.00 | Direct (D) | No | F6
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 7,500.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 22,500.00 | Direct (D) | No | F7
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 50,000.00 | Direct (D) | No | F8
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Derakhshan Behrad Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 100,000.00 | Direct (D) | No | F9
| Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Nofi Michael Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 24,375.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 24,375.00 | Direct (D) | No | F1
| Open filing 0001705477-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Nofi Michael Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 48,750.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 48,750.00 | Direct (D) | No | F2
| Open filing 0001705477-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 15,995.00 | Direct (D) | No | — | Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 6,718.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 22,713.00 | Direct (D) | No | — | Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,439.00 | 43.8081 | 106,847.9559Derived: shares × price per share. Exact value 106847.955900. | 20,274.00 | Direct (D) | No | F1, F2
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 59.00 | 44.4142 | 2,620.4378Derived: shares × price per share. Exact value 2620.437800. | 20,215.00 | Direct (D) | No | F1, F3
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 99.00 | 44.5019 | 4,405.6881Derived: shares × price per share. Exact value 4405.688100. | 20,116.00 | Direct (D) | No | F1, F4
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,419.00 | 43.7985 | 105,948.5715Derived: shares × price per share. Exact value 105948.571500. | 17,697.00 | Direct (D) | No | F1, F5
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,781.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 11,563.00 | Direct (D) | No | F6
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 6,718.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 20,157.00 | Direct (D) | No | F7
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 32,500.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 32,500.00 | Direct (D) | No | F8
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | MOORE JOHN R Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,000.00 | Direct (D) | No | F9
| Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 17,969.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 48,584.00 | Direct (D) | No | — | Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 21,875.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 70,459.00 | Direct (D) | No | — | Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,782.00 | 43.6408 | 383,253.5056Derived: shares × price per share. Exact value 383253.505600. | 61,677.00 | Direct (D) | No | F1, F2
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,276.00 | 43.6582 | 361,315.2632Derived: shares × price per share. Exact value 361315.263200. | 53,401.00 | Direct (D) | No | F1, F3
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 913.00 | 44.33 | 40,473.29Derived: shares × price per share. Exact value 40473.2900. | 52,488.00 | Direct (D) | No | F1, F4
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 17,969.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 35,938.00 | Direct (D) | No | F5
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 21,875.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 65,625.00 | Direct (D) | No | F6
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | KOCH KEVIN Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000.00 | 0.00 | 0Derived: shares × price per share. Exact value 0.0000. | 100,000.00 | Direct (D) | No | F7
| Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. Common Stock | 6.7 | 7,298,521 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001274173-26-000238 Dispute this row |
| FMR LLC COMMON STOCK | 0.9 | 970,920.00 | 09/30/2026 Filed 2026-11-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-26-002741 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 0.9 | 970,920.00 | 09/30/2026 Filed 2026-11-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-26-002741 Dispute this row |
| Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share | 9.5 | 10,215,455.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097206 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share | 9.5 | 10,215,455.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097206 Dispute this row |
| Senai Asefaw, M.D. Common Stock, $0.0001 par value per share | 9.5 | 10,215,455.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097206 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share | 8.3 | 8,961,631.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097206 Dispute this row |
| RA Capital Management, L.P. Common Stock, par value $0.0001 per share | 7.8 | 8,392,730.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000922 Dispute this row |
| Peter Kolchinsky Common Stock, par value $0.0001 per share | 7.8 | 8,392,730.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000922 Dispute this row |
| Rajeev Shah Common Stock, par value $0.0001 per share | 7.8 | 8,392,730.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000922 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share | 7.8 | 8,392,730.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000922 Dispute this row |
| Baker Bros. Advisors LP Common Stock, par value $0.0001 per share | 3.4 | 3,701,719.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097041 Dispute this row |
| Baker Bros. Advisors (GP) LLC Common Stock, par value $0.0001 per share | 3.4 | 3,701,719.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097041 Dispute this row |
| Julian C. Baker Common Stock, par value $0.0001 per share | 3.4 | 3,701,719.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097041 Dispute this row |
| Felix J. Baker Common Stock, par value $0.0001 per share | 3.4 | 3,701,719.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-097041 Dispute this row |
| FMR LLC COMMON STOCK | 5.1 | 5,489,135.00 | 06/30/2026 Filed 2026-08-06 | SCHEDULE 13G | Open filing 0000315066-26-001979 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 5.1 | 5,489,135.00 | 06/30/2026 Filed 2026-08-06 | SCHEDULE 13G | Open filing 0000315066-26-001979 Dispute this row |
| Novo Holdings A/S Common Stock, par value $0.0001 per share | 4.9 | 5,350,000.00 | 04/23/2026 Filed 2026-04-27 | SCHEDULE 13D/AAmendment 6 | Open filing 0001388325-26-000014 Dispute this row |
| JANUS HENDERSON GROUP PLC Common Stock | 5.5 | 5,915,556 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001274173-26-000124 Dispute this row |
| Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share | 6.2 | 6,541,210.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-016362 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share | 6.2 | 6,541,210.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-016362 Dispute this row |
| Senai Asefaw, M.D. Common Stock, $0.0001 par value per share | 6.2 | 6,541,210.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-016362 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share | 5.5 | 5,778,924.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-016362 Dispute this row |
| JANUS HENDERSON GROUP PLC Common Stock | 4.7 | 4,979,331 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001274173-25-000268 Dispute this row |
| RA Capital Management, L.P. Common Stock, par value $0.0001 per share | 9.9 | 10,428,437.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-25-000488 Dispute this row |
| Peter Kolchinsky Common Stock, par value $0.0001 per share | 9.9 | 10,428,437.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-25-000488 Dispute this row |
| Rajeev Shah Common Stock, par value $0.0001 per share | 9.9 | 10,428,437.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-25-000488 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share | 9.9 | 10,428,437.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-25-000488 Dispute this row |
| Baker Bros. Advisors LP Common Stock, par value $0.0001 per share | 6.9 | 7,305,940.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-078659 Dispute this row |
| Baker Bros. Advisors (GP) LLC Common Stock, par value $0.0001 per share | 6.9 | 7,305,940.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-078659 Dispute this row |
| Julian C. Baker Common Stock, par value $0.0001 per share | 6.9 | 7,305,940.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-078659 Dispute this row |
| Felix J. Baker Common Stock, par value $0.0001 per share | 6.9 | 7,305,940.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-078659 Dispute this row |
| Perceptive Advisors LLC Common Stock, par value $0.0001 per share | 4.4 | 4,639,949 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0000950170-25-108936 Dispute this row |
| Joseph Edelman Common Stock, par value $0.0001 per share | 4.4 | 4,639,949 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0000950170-25-108936 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, par value $0.0001 per share | 4.4 | 4,639,949 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0000950170-25-108936 Dispute this row |
| JANUS HENDERSON GROUP PLC Common Stock | 5.2 | 5,503,349 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001274173-25-000244 Dispute this row |
| BlackRock, Inc. Common Stock | 5.5 | 5,824,866 | 06/30/2025 Filed 2025-07-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0002052113-25-003023 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,687,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 103,592 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.